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Lipid Mediator Profiles Predict 
Response to Therapy with an Oral 
Frankincense Extract in Relapsing-
Remitting Multiple Sclerosis
Klarissa Hanja Stürner  1 ✉, Oliver Werz  2, Andreas Koeberle  2,3, Markus otto  4,  
Ole pless  5, Frank Leypoldt1,6, Friedemann paul7,8 & Christoph Heesen9
Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be 
affected by frankincense extracts. We performed LM profiling by metabololipidomics in plasma samples 
from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took a standardised frankincense 
extract (SFE) daily for eight months in a clinical phase IIa trial (NCT01450124) and in 28 age- and 
gender-matched healthy controls. Magnetic resonance imaging, immunological outcomes and serum 
neurofilament light chain levels were correlated to changes in the LM profiles of the RR-MS cohort. 
Eight out of 44 analysed LMs were significantly reduced during an eight-month treatment period 
by the SFE and seven of these eight significant LM derive from the 5-lipoxygenase (5-LO) pathway. 
Baseline levels of 12- and 15-LO products were elevated in patients who exhibited disease activity 
(EDA) during SFE treatment compared to no-evidence-of-disease-activity (NEDA) patients and could 
predict treatment response to the SFE in a prediction model at baseline. Oral treatment with an SFE 
significantly reduces 5-LO-derived LMs in RR-MS patients during an eight-month treatment period. 
Treatment response to an SFE, however, seems to be related to 12-,15-LO and cyclooxygenase product 
levels before SFE exposure. Further studies should confirm their biomarker potential in RR-MS and SFE 
treatment.
Multiple sclerosis is the most common debilitating chronic autoimmune disease of the central nervous system 
affecting more than 2 million predominantly young female adults worldwide1. Oral drugs exhibiting a favourable 
safety profile for the treatment of relapsing-remitting multiple sclerosis (RR-MS) are of high interest for patients 
and treaters because of the treatment’s long-term perspective in RR-MS. Boswellic acids (BAs), the main bio-
logically active ingredients of frankincense, are orally available and exhibit anti-inflammatory activities in com-
bination with beneficial data on safety and tolerability2,3. Of these BA-associated anti-inflammatory responses, 
the best described are pharmacologically induced changes of the lipid mediator (LM) profile, in particular the 
inhibition of 5-lipoxygenase (5-LO)2, an enzyme which has been implicated in MS pathogenesis due to its expres-
sion in RR-MS brain lesions4. Little is known about the impact of LMs and their relevance to MS pathology, 
however accumulating data indicates that the importance of LMs has been underestimated in MS to date5 and 
that LM-producing enzymes are involved in disease pathogenesis and progression6,7. Consequently, we analysed 
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the LM profile in RR-MS patients before and after oral BA-treatment with an SFE for eight months in a clinical 
phase IIa trial.
Material and Methods
We performed a bicentric, phase IIa, open-label, baseline-to-treatment trial between 2011 and 2017 with an 
orally available SFE produced by Alpinia Institute for Life Sciences AG (Walenstadt, Switzerland) at two German 
tertiary academic MS centers (SABA Trial8, NCT01450124). The study was approved by the German Federal 
Institute for Drugs and Medical Devices (BfArM, Approval No. 4036771), and by the local ethics committees 
(Ethik-Kommission der Ärztekammer Hamburg, Approval No. PVN3389 and PVN2758 and Ethikkommission 
der Charité – Universitätsmedizin Berlin, Approval No. ZS EK 13572/09). All participants gave their writ-
ten informed consent at screening and the study and all experiments were conducted in accordance with the 
Declaration of Helsinki and with good clinical practice. Plasma and serum samples were collected before the 
start of treatment and at month 8, respectively, and stored at −80 °C, as described previously8. Samples originated 
Figure 1. Lipid mediator profile in 28 untreated RR-MS patients (black, upper panel a) and changes (delta 
values) in the identical patient cohort after 8 months of treatment with a standardised frankincense extract 
(blue, lower panel b). Individual data are plotted as dots with median and interquartile range, in the lower panel 
data are presented as median delta values from baseline with interquartile range.
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from n = 28 RR-MS patients who took 3600 to 4800 mg of an SFE daily and from 28 age- and gender-matched 
healthy controls. LM profiling by metabololipidomics was performed by analysing a panel of 44 LMs using ultra-
performance liquid chromatography ESI tandem mass spectrometry (UPLC-MS-MS)9. Signal intensities (peak 
areas) were normalized to the internal standard PGB1 to correct for differences in sample preparation.
Statistics were carried out using R10 and the packages ggplot211 and corrgram12. For calculating the 
fold-increase in RR-MS patients versu healthy controls the median value for each LM of the healthy control cohort 
was used as normalization value. LM analysis of longitudinal samples was performed using paired Wilcoxon tests 
(baseline vs. follow-up) with Bonferroni adjustment. LMs were also correlated with magnetic resonance imag-
ing (MRI), immunological, biomarker outcomes (collected as described previously8) and serum neurofilament 
light chain (NfL) concentrations. NfL and Glial fibrillary acidic protein (GFAP) were measured using the Simoa 
NF-light® assay (Quanterix, USA). For analysing correlations, descriptive statistics with a Spearman’s of p < 0.05 
were used. For further analysis, patients in the SABA trial were subdivided according to no-evidence-of-disease 
activity (NEDA) criteria (defined by lack of a relapse, lack of new T2 lesions and new contrast-enhancing lesions 
(CEL) and no confirmed disease progression (NEDA3)) into a NEDA group and an evidence of disease activity 
(EDA) patient group. EDA patients had at least either a relapse, a new T2 lesion or CEL or a confirmed disease 
progression in EDSS during the treatment phase of the trial. Combined analysis for prediction of NEDA status 
using LM expression was performed using the Combiroc Online Tool13.
Results
Lipid mediator expression differs between healthy controls and MS patients. Except for 
12-HHT, measured LMs were significantly higher in RR-MS patients compared to healthy age- and gen-
der-matched controls with the topmost fold-increase (>1000-fold) in five LMs being: the three 5-LO-derived 
LM lipoxin A4 and/or isomers, 5,12-di-hydroxyeicosatetraenoic acid (5,12-diHETE), leukotriene B4 (LTB4), and 
the two 12- or 15-LO-derived LM protectin D1 (PD1) and protectin DX (PDX). Thirty-one LMs (i.e. 70%) were 
>100-fold more abundant in RR-MS than in healthy donors (Fig. 1a, Supplemental Table S1).
An eight-month treatment with an SFE changes the LM profile in RR-MS patients. After receiv-
ing a SFE for eight months, a general decrease of LMs was observed (Figs. 1b and 2). However, only eight of 
44 analysed LMs were significantly reduced in the 28 RR-MS patients. These were: 9-HETE, lipoxin A4 and/or 
isomers, lipoxin B4 and/or isomers, 5,15-diHETE, LTB4, 5-HETE and its metabolites 5-oxo-eicosatetraenoic acid 
(5-oxo-ETE), and 5S-hydroxy-6E,8Z,11Z-eicosatrienoic acid, (5-HETrE). Seven of these eight LMs are generated 
Figure 2. Treatment effect of a standardised frankincense extract (SFE) on selected lipid mediators, 
neurofilament light chain, contrast enhancing lesion volume, and immunological outcomes in the SABA trial 
(n = 28 patients; n = 12 NEDA and n = 16 EDA patients). HC: healthy controls. Pre: baseline values before start 
of treatment, post: values after 8 months of continuous SFE treatment. ***p < 0.001, **p < 0.01, *p < 0.05.
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by the 5-LO pathway, while 9-HETE is predominantly produced by non-enzymatic oxidation of arachidonic acid. 
For seven of these LMs the reduction was more pronounced in EDA patients when compared to MS patients 
fulfilling NEDA criteria during SFE treatment (Figs. 2, 3b and Supplemental Table S2) thereby triggering further 
analyses of the NEDA and EDA subgroups. Only for 5-oxo-ETE, a bioactive metabolite of 5-HETE, the reduction 
during SFE treatment was more pronounced in NEDA patients (Fig. 2 and Supplemental Table 2).
Baseline expression of 12- and 15-LO derived lipid mediators predicts treatment response to an 
SFE. When we analysed the LM profile of NEDA and EDA patients of the trial cohort at baseline, certain LMs 
were already found to be increased in the trial subjects, later defined as EDA RR-MS patients (Fig. 3a). When ana-
lysing the 7 LMs with the lowest p-values (all p ≤ 0.01: PD1, 11-HETE, 12-HETE, 15-HETE, 8-HETE, 15-HETrE, 
15-HEPE) for their performance in predicting the response to SFE treatment, the ROC curve yielded results of 
83% for sensitivity and 100% for specificity (AUC 0.958, Fig. 4), indicating that these LMs could be useful as 
biomarkers to predict therapy response to an SFE prior to treatment. For the majority of these markers, 12- and 
15-LOs are involved in their biosynthesis.
LM correlations with biomarkers of MS are dependent on treatment response to an SFE. 
Correlation analysis (Fig. 5, Suppl. Tables S3–5) between LM and MRI, immunological and NfL outcomes in the 
complete SFE-treated patient cohort revealed that LMs showed only moderate correlations in the total patient 
cohort. However, when the SFE-treated RR-MS patient cohort was split according to NEDA criteria, the correla-
tion matrices revealed differing patterns in the NEDA versus EDA groups (Fig. 5, middle and right panel).
For NEDA patients, three strong negative correlations involving LMs were apparent (Fig. 6a and Suppl. 
Table 4). These were: 1) PGE1 and the proportion of IL-10 positive CD8+ T cells (r = −0.754), 2) PGE1 and the 
proportion of IL-17+ CD4+ T cells (r = −0.736) and 3) CD86 expression on myeloid dendritic cells and the 
5-LO-derived LM resolvin E1 (RvE1, r = −0.645). The significant strong positive correlations involving LMs in 
NEDA patients were changes in: 1) CTLA-4 expression and 12-HHT (r = 0.728) and 2) PGD2 and the propor-
tion of Foxp3+ CD4+ T cells (r = 0.727). Intra-individual NfL concentration changes during the trial showed a 
strong negative correlation with the significantly decreased 5-LO products 5-HETrE (r = −0.637) and 5-oxo-ETE 
(r = −0.648) and additionally with 12-HHT (r = −0.714). These negative correlations between NfL and LMs were 
only seen in the NEDA patient group.
Contrastingly, positive correlations were found in EDA patients for TGF-β and 12-HHT and for several 
12/15-LO products and CD86 surface expression on myeloid dendritic cells (Fig. 6b and Suppl. Table 5). Strong 
Figure 3. Upper Panel a: Baseline expression of selected LMs (p ≤ 0.01) in NEDA (in green, n = 12) versus 
EDA MS patients (orange, n = 16) of the SABA trial. LM expression is plotted as violin plots indicating median 
(dashed line) and interquartile range (dotted line) of the LM signal intensity measured as peak area. Lower 
Panel b: Changes (delta values) in NEDA (n = 12, green) versus EDA (n = 16, orange) SABA patients after eight 
months of treatment with a standardised frankincense extract. Individual data are plotted as median of delta 
values from individual baseline values of the fold increase versus healthy controls with interquartile range.
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negative correlations were evident in EDA patients for serum IL-17 levels and CTLA-4 (r = −0.696), PGD2 
(r = −0.615) and PGE2 (r = −0.604), respectively.
When comparing the correlation matrices of NEDA and EDA patients, the most prominent difference indi-
cated that COX-derived LMs correlated with other LMs only in EDA patients and failed to do so in the NEDA 
patient cohort (Fig. 5). The most striking single difference between the NEDA and EDA subgroups during SFE 
treatment was a correlation between CD86 expression on myeloid dendritic cells and the 5-LO-derived LM RvE1 
(Fig. 6C), which was moderate and positive in EDA RR-MS patients (r = 0.55) and strong and negative in NEDA 
patients (r = −0.645).
Irrespective of the analysed LMs prominent correlations among the other analysed biomarkers in the total 
SABA patient cohort were: 1) changes in NfL serum concentration and the CEL volume, 2) the proportion of 
IL-17+ CD4+ T cells and CD40 surface expression of myeloid dendritic cells and 3) changes in NfL serum 
concentration and the proportion of IL-10+ CD8+ T cells (Suppl. Figures 1–3). In NEDA patients changes in 
CTLA-4 expression on CD4+ T cells and the volume of CEL in MRI showed a strong correlation (r = −0.836, 
Suppl. Figure 4). GFAP serum levels remained unaltered during treatment (Suppl. Figure 5). Most of these obser-
vations confirm previous reports8,14,15 and can serve as a quality control of the data set.
Figure 4. (a) Overlay of multiple ROC curves for the LMs of Fig. 3a in the CombiROC analysis. (b) Results 
from the CombiROC analysis for the prediction of EDA status/Non-Response to SFE treatment from baseline 
LM levels.
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Discussion
This is the first longitudinal study of LMs in an RR-MS patient cohort, and the first longitudinal analysis of a 
correlation of LMs and several biomarkers including MRI, immune cell subsets and NfL in peripheral blood of 
RR-MS patients and in patients treated with an SFE. The significant upregulation of LMs in this RR-MS patient 
cohort compared to healthy controls suggests that LM pathways are involved in the immunopathology of MS. 
When analysing data from a small clinical phase IIa trial with a 5-LO-inhibiting SFE, we observed a significant 
decline in 5-LO products after an eight-month treatment period, although in vitro data previously implied that 
BAs have an IC50 for 5-LO that is unlikely to be reached in vivo16. The use of an extract containing different BAs 
and related bioactive triterpene acids might provide an explanation for this result by exhibiting synergistic effects 
and thereby more efficiently inhibiting 5-LO. However, despite this clear effect on 5-LO products, the treatment 
response to the SFE in RR-MS patients seems more complex: LMs form an elaborated network and inhibition of 
single enzymes skews the LM metabolome in a cell-specific fashion17, e.g. 5-LO inhibitors reduce leukotrienes 
in M1 but less so in M2 macrophages. Furthermore, MS itself is a heterogeneous disease or may even represent 
a group of diseases that exhibit differences in treatment response to several established MS disease-modifying 
therapies, complicating the analysis of patient responses and disease outcomes. Our observations suggest that 
the treatment response to an SFE is not associated with 5-LO inhibition in RR-MS. However, upregulation of 
12- or 15-LO and COX activity in RR-MS might define an MS subtype that has a suboptimal response to SFE 
treatment. This matches previous observations of an involvement of the 12- or 15-LO and COX in more active 
RR-MS patients18,19. The strong positive correlation between 12/15-LO-derived LMs and the surface expression of 
CD86 in dendritic cells in the EDA RR-MS group is in line with previous animal studies showing that 12/15-LO 
regulates the maturation process of dendritic cells and its inhibition favours TH17 differentiation20. Such a skew 
towards TH17 differentiation in the active EDA RR-MS group is evident from the positive correlations of 12- or 
15-LO-derived LM and IL-17+ CD8+ T cells (Fig. 5). Considering the positive correlations between serum IL-17 
levels and prostaglandins that promote IL-17 production and TH17 expansion21, all these observations suggest 
the presence of an IL-17-driven phenotype in the active RR-MS cohort that is unaffected by oral SFE treatment.
5-LO and particularly the 12/15-LO-derived LM can act as agonists of the peroxisome proliferator-activated 
receptor-γ (PPARγ)22,23, a transcription factor with relevance to the pathogenesis of MS and exhibiting poten-
tial as a therapeutic target. Hence, 5-LO- or 12/15-LO-deficient mice show a significant exacerbation of the 
disease course during EAE24. Upregulation of the associated LMs might therefore represent an endogenous 
anti-inflammatory and neuroprotective mechanism in MS patients. As this effect is more pronounced in RR-MS 
patients with disease activity during SFE treatment, the increase of 5-LO and 12/15-LO-derived LM might indi-
cate that PPARγ-signalling is already upregulated in non-responding patients and thereby indirectly revealing 
one potential mechanism of action of the SFE in this trial. The opposite correlations of the pro-resolving LM RvE1 
and CD86 expression of myeloid dendritic cells in the NEDA and non-responding EDA RR-MS subgroup further 
support the idea of pre-existing MS subgroups or phenotypes in which different pathways are involved in disease 
pathogenesis. Thus, RvE1 has been previously described as being able to decrease disease severity by suppressing 
autoreactive T cells in an MS mouse model25.
The correlated changes in Foxp3 and CTLA-4 expression in and of CD4+ T cells, CD86 expression of myeloid 
dendritic cells and several COX-controlled LM in NEDA patients and their absence in EDA MS patients with 
Figure 5. Correlation matrices of lipid mediators and biomarkers of the SABA trial; positive correlations are 
blue, negative correlations are red. Only correlations with a Spearman’s of p < 0.05 are plotted. The thinner the 
dot, the smaller the p-value. LMs are ordered by key enzyme. Left: total SABA patient cohort (n = 28), middle: 
NEDA patients (n = 12), right: active EDA RR-MS patients, i.e. Non-responders (n = 16). Exact values of the 
correlations are given in the Supplementary Material. CEL: contrast enhancing lesion, M0-M8: treatment phase 
of the trial.
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higher COX-controlled LM levels could also indicate the involvement of another dioxygenase in active RR-MS 
patients. One such dioxygenase that is known to be inhibited by COX is indoleamine 2,3-dioxygenase (IDO), a 
key enzyme in the kynurenine pathway, which exhibits immune checkpoint function in MS26,27. A pre-existing 
enhancement of COX activation in active RR-MS patients is thus likely to lower IDO expression and thereby pre-
vent an immune therapeutic effect of BAs in these patients, while in the NEDA patients, the lower COX activity 
allows BAs to take effect.
Figure 6. Strongest LM correlations in (a) NEDA and (b) EDA RR-MS patients of the SABA trial; (c) shows the 
correlation plots for Resolvin E1 in NEDA (left) versus EDA (right) RR-MS patients of the SABA trial.
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Conclusion
Oral treatment with an SFE significantly reduces bioactive 5-LO-derived LMs, MRI disease activity, and periph-
eral neurofilament light chain concentrations in RR-MS patients during an eight-month treatment period. 
However, inhibition of 5-LO per se is not associated with a treatment response to an SFE. In EDA patients during 
SFE treatment, LMs produced by 12- or 15-LOs are primarily upregulated before the start of the treatment and 
might be useful as predictors of an SFE-mediated treatment response in the future. When comparing correlation 
plots of the parameters analysed in the total SABA patient cohort, in the NEDA responder subgroup and the EDA 
treatment failure patient subgroup, different correlation profiles can be detected indicating a difference in the reg-
ulation of 12/15-LO- and COX-derived LM in these respective subpopulations and their associated immunolog-
ical profiles. Further studies should investigate the potential of LMs as biomarkers in RR-MS and the mechanism 
of frankincense extracts in the suppression of disease activity in RR-MS.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Received: 6 December 2019; Accepted: 29 April 2020;
Published: xx xx xxxx
References
 1. Browne, P. et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 83, 1022–1024 
(2014).
 2. Abdel-Tawab, M., Werz, O. & Schubert-Zsilavecz, M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic 
and clinical data. Clin. Pharmacokinet 50, 349–369 (2011).
 3. Di Lorenzo, C. et al. Plant food supplements with anti-inflammatory properties: a systematic review (II). Crit. Rev. Food. Sci. Nutr. 
53, 507–516 (2013).
 4. Whitney, L. W., Ludwin, S. K., McFarland, H. F. & Biddison, W. E. Microarray analysis of gene expression in multiple sclerosis and 
EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 121, 40–48 (2001).
 5. Palumbo, S. Pathogenesis and Progression of Multiple Sclerosis: The Role of Arachidonic Acid–Mediated Neuroinflammation, (Codon 
Publications, Brisbane, Australia, 2017).
 6. Kihara, Y. et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 
106, 21807–21812 (2009).
 7. Lam, M. A. et al. Absence of systemic oxidative stress and increased CSF prostaglandin F2alpha in progressive MS. Neurol 
Neuroimmunol Neuroinflamm 3, e256 (2016).
 8. Sturner, K. H. et al. A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA 
phase IIa trial). J Neurol Neurosurg Psychiatry 89, 330–338 (2018).
 9. Koeberle, A. et al. SAR studies on curcumin’s pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent 
and selective novel inhibitors of 5-lipoxygenase. J Med Chem 57, 5638–5648 (2014).
 10. Team, R.C. R: A language and environment for statistical computing. (R Foundation for Statistical Computing,Vienna, Austria, 
2017).
 11. Hadley, W. ggplot2: Elegant Graphics for Data Analysis, (Springer-Verlag New York, 2016).
 12. Friendly, M. Corrgrams: Exploratory Displays for Correlation Matrices. The American Statistician 56, 316–324 (2002).
 13. Mazzara, S. et al. CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Sci Rep 7, 45477 
(2017).
 14. Barro, C. et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. 
Brain 141, 2382–2391 (2018).
 15. Iezzi, G. et al. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-
producing CD4+ T cells. Proc Natl Acad Sci USA 106, 876–881 (2009).
 16. Siemoneit, U. et al. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological 
relevance. Eur J Pharmacol 606, 246–254 (2009).
 17. Werner, M. et al. Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. FASEB J 33, 
6140–6153 (2019).
 18. Lotsch, J. et al. Machine-learning based lipid mediator serum concentration patterns allow identification of multiple sclerosis 
patients with high accuracy. Sci Rep 8, 14884 (2018).
 19. Pruss, H. et al. Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot 
trial. PLoS One 8, e55859 (2013).
 20. Rothe, T. et al. 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest 125, 
1944–1954 (2015).
 21. Tsuge, K., Inazumi, T., Shimamoto, A. & Sugimoto, Y. Molecular mechanisms underlying prostaglandin E2-exacerbated 
inflammation and immune diseases. Int Immunol (2019).
 22. Dreyer, C. et al. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome 
proliferator-activated receptors (PPAR). Biol Cell 77, 67–76 (1993).
 23. O’Flaherty, J. T. et al. 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta 1736, 228–236 (2005).
 24. Emerson, M. R. & LeVine, S. M. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 
5-lipoxygenase. Brain Res 1021, 140–145 (2004).
 25. Poisson, L. M. et al. Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic 
Animal Model of Multiple Sclerosis. J Biol Chem 290, 30697–30712 (2015).
 26. Fakan, B., Szalardy, L. & Vecsei, L. Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple 
Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. Int J Mol Sci 20(2019).
 27. Jung, I. D. et al. COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-
derived dendritic cells. Int Immunopharmacol 10, 760–768 (2010).
Acknowledgements
We thank all our patients and healthy volunteers who participated in this study. We thank Birte Behrens, Nina 
Kursawe, Nina Verse and Stephen Meier for technical assistance with the immunological measurements, NfL 
and GFAP measurements, respectively. We thank Alpinia Institute for Life Sciences AG for providing us with a 
standardised frankincense extract free of charge. This work was supported by the Bundesministerium für Bildung 
9Scientific RepoRtS |         (2020) 10:8776  | https://doi.org/10.1038/s41598-020-65215-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
und Forschung (BMBF, Förderkennzeichen 0315610–0315620 and Förderkennzeichen 16GW0082) in the 
context of NEU2 and by the Competence Net Neurodegenerative Dementias (project: FTLDc 01GI1007A). The 
lipid mediator analyses were supported by Alpinia Institute for Life Sciences AG, Switzerland. We acknowledge 
financial support by the DFG within the funding programme Open Access Publizieren. None of the funding 
sources had any role in designing the study, in collection, analysis, or interpretation of data, or in writing the 
article.
Author contributions
K.H.S., C.H., F.P. and O.W. designed the study, K.H.S., F.P., O.P. collected data. K.H.S., O.W., A.K., M.O., F.L., F.P., 
O.P. and C.H. analysed the data. K.H.S. and F.L. performed the statistical analysis. K.H.S., O.W., A.K., F.L., F.P. and 
C.H. wrote the report. K.H.S., O.W., A.K., M.O., F.L., F.P., O.P. and C.H. interpreted data and revised the report.
Competing interests
Klarissa Hanja Stürner has received personal fees and travel grants from Bayer, Biogen, MerckSerono and Genzyme 
during the last 5 years. F. Leypoldt reports speaker honoraria from Bayer, Roche, Novartis, Fresenius, travel funding 
from Merck, Grifols and Bayer and serving on advisory boards for Roche, Biogen and Alexion. Friedemann Paul has 
received honoraria and research support from Alexion, Bayer, Biogen, Chugai, MerckSerono, Novartis, Genzyme, 
MedImmune, Shire, Teva, and serves on scientific advisory boards for Alexion, MedImmune and Novartis. He 
has received funding from Deutsche Forschungsgemeinschaft (DFG Exc 257), Bundesministerium für Bildung 
und Forschung (Competence Network Multiple Sclerosis), Guthy Jackson Charitable Foundation, EU Framework 
Program 7, National Multiple Sclerosis Society of the USA. Ole Pless, Oliver Werz and Andreas Koeberle have 
nothing to disclose and declare no potential conflict of interest. Markus Otto served as consultant for Biogen, Roche, 
Axon Neuroscience and Fujirebio. C. Heesen has received travel and research grants from Biogen, Genzyme, Merck, 
Novartis and Roche.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65215-6.
Correspondence and requests for materials should be addressed to K.H.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
